<<
>>

.. : - . .... . . . ., 2011. .. IV : .
. ... . . . ., 2009. .., .., - . . , . .: . . . , 80- . .. . : , 1999. .., .., ., .. . .:
. . .. , .. . .: , 2010: 427-475. .., .. . . , - . 2002; 47(4): 20-23. .. : . .... . . . ., 2009. , . . .: , 2004. .. : . .... . . . ., 1998. .., .. - . .: , 1995. .., .. . .: , 1998. .. - (): 10- . , . 2000; 1: 39-43. .., .., .. : . .: , 2010. .. : . 2011; 5: 8. .., .., ..
. . .- . . 1997; 2: 30-35. .., P.S. . .: , 2006. .., .., .., .. - . 2009; 5: 19-24. .., .., ..
( [Hileflox]), 750 , -008842/10, . . . . 2010; 4(16): 34-36. .. - - : .
. ... - . . ., 2011. .., .. . , - . . 1994; 3(2): 53-58. .. . .: . . 1. ., 1997: 78-86. .. . . . . . 2001; 3(4). Acar J.F. A comparison of side effects of le- vofloxacin to other agents concerning the ecological and microbioloogical effects on normal human flora. Chemotherapy 2001; 47: 15-23. Appelbaum P.C. et al. /-Lactamase productions and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin/clavula- nate, cefoxitin, imipenem, and metronida- sole of 320 non-Bacteroides fragilis Bacte- roides isolates and 129 fusabacteria from 28
U.S. centres. Antimicrob. Agents Chemother. 1990; 34: 1546-1550. Azuma Y., Shinohara M., Wang P.L., Ohura
K.  Quinolones alter defense reactions mediated by macrophages. Int. Immunopharma- col. 2001; 1: 179-187. Barry A.L., Fuchs P.S. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin and fleroxacin. Antimicrob. Agents Chemother. 1991; 35: 955-960. Berfino J., Fish D. The safety profile of the fluoroquinolones. Clin. Ther. 2000; 22: 798-817. Ball P., Mandell L., Pafou G. ef al. A new respiratory fluoroquinolone, oral gemifloxa-

: a safety profile in context. Int. J. Antimi- crob. Agents 2004; 23: 421-429. Blondeau J., Missaghi B. Gemifloxacin: a new fluoroquinolone. J. Exp. Opin. Pharma- cother. 2004; 5(5): 1117-1152. Cooper 4.. In vitro activity of tosufloxa- cin, a new quinolone antibacterial agent. J. Antimicrob. Chemother. 1992; 29: 639-647. Dalhoff A. In vitro activities of quinolones. Exp. Opin. Invest. Drugs 1999; 8(2): 123-137. Dalhoff A., Shalit I. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 2003; 3(6): 359-371. Diz Dios P., Tomas Carmona /., Limeres Posse J. ef al. Comparative efficacies of amoxicillin, clindamycin, and moxifloxacin in prevention of bacteremia following dental extractions. Antimicrob. Agents Chemother. 2006; 50(9): 2996-3002. Delfino D., Bonina L., Berlinghieri M.C., Mastroeni P. Effects of a new quinolone derivative, ciprofloxacin, on some professional phagocytic cell functions. Chemioterapia 1985; 4: 463-466. Felmingham D., Robbins M.J., Ingley K.
et al. In vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J. Antimicrob. Chemother. 1997; 39(Suppl. B): 43-49. Finegold S.M. In vitro activity of temaflox- acin against anaerobic bacteria: a comparative study. J. Antimicrob. Chemother. 1991; 28(Suppl. C): 25-30. Hooper D.C. Mechanisms of quinolone resistance. In: Quinolone antimicrobial agents, 3rd edn. Ed. by D.C. Hooper, E. Rubenstein. Washington, DC: American Society for Microbiology Press, 2003: 41-67. Gollapudi S.V., Chuah S.K., Harvey T. ef al. In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis. Antimicrob. Agents Chemother. 1993; 37: 1711-1712. Goldstein E.J. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxa- cin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob. Agents Chemother. 1992; 36: 1158-1162. Gwalfney J.M. Jr., Wiesinger B.A., Pafrie
J.T. Acute community-acquired bacterial sinusitis: The value of antimicrobial treatment and the natural history. J. Clin. Infect. Dis. 2004; 38(2): 227-233. Mandell L., Tillotson G. Streptococcus pneumoniae: drug resistance and optimal therapeutic approaches. J. Today Ther. Trends 2004; 22(2): 121-145. Marnett L.J., Wright T.L., Crews B.C. et al.
Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J. Biol. Chem. 2000; 275: 13427-13430. Neuman M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin. Pharmacokin. 1988; 14: 96-121. Perry C.M., Ormrod D., Hurst M., On- rust S.V. Gatifloxacin: a review of its use in the management of bacterial infections. J. Drugs. 2002; 62(1): 169-207. Rubinstein E. History of quinolones and their side effects. Penetrationinternational update on levofloxacin and ofloxacin. Biomedis Int. Ltd., 2000: 71. Ono Y., Ohmoto Y., Ono K. et al. Effect of grepafloxacin on cytokine production in vitro. J. Antimicrob. Chemother. 2000; 46: 9194. Stunkel K.G., Hewlett G., Zeiler H.J. Ciprofloxacin enhances T cell function by modulating interleukin activities. Clin. Exp. Immunol. 1991; 86: 525-531. Solomcin J.S. et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/clastatin for intra-abdominal infections. Ann. Surg. 1996; 3: 303315. Spangler S.K.. et al. Activity of CP-99, 219, compared to those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piper- acillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 1994; 38: 2471-2476. Spangler S.K. et al. Susceptibility of anaerobic bacteria to trovofloxacin: comparison with other quinolones and non-quino- lone antibiotics. Inf. Dis. In Clin. Pract. 1996; 5(Suppl. 3): 101-109. Szczypka M., Obminska-Domoradzka .
Wp3yw fluorochinolonow na aktywnoce- ae makrofagow otrzewnowych myszy. Med. Wet. 2002; 58: 68-73. SzczypkaM., Obminska-MrukowiczB. Comparative effects of fluoroquinolones on subsets of T lymphocytes in normothermic and hyperthermic mice. J. Vet. Pharmacol. Ther. 2003; 26: 253-258. Szczypka M., Gaweda B., Obminska-Mrukowicz B. Effects of marbofloxacin in the activity of macrophages and T and cells in non-infected and E. coli-infected mice. 2004; 13/54(12): 79-84. Thorpe R. Interleukin 2. In: Cytokines. Ed. by A.R. Mire-Sluis, R. Thorpe. San Diego, London, Boston, New York, Sydney, Tokyo, Toronto: Academic Press, 1998: 19-34. Yagawa K. Latest industry information on the safety profile of levofloxacin in Japan. Chemotherapy 2001; 47(3): 38-43. YYagsiaff A.J., Balfour J.H. Grepafloxacin. Drugs 1997; 53: 817-824. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquino- lone, and its potential relation to therapeutic efficacy. Clin. Drug Invest. 1999; 17(5): 365387. Wong J.P., Schnell G., Simpson M., Sara- volac E. Effects of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide and intracellular killing of Staphylococcus aureus by murine macrophages. Ar- tif. Cells Blood Substit. Immobil. Biotech- nol. 2000; 28: 415-428.

<< | >>
: .. , .. , .. . 2012. 2012

:

- - - -
- - - - - - - - - - - - - -